glp-1 receptor agonists effectiveness comparison Clinical efficacy results from clinical trials comparing different GLP-1 Receptor Agonists for Weight
Description
Even the 4mg dose saw 61% and 44% losing 15 and 20% body weight respectively
doi:10.1161/CIRCULATIONAHA.122.059595 12
The company is already seeking the FDAs approval of orforglipron, which could occur by early next year
History of Science: Evolution of pharmacology
In 2008, this report was published: Title: Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinsons disease
